



**FOUNDATION FUNDING OPPORTUNITIES: APRIL 9, 2021**

Please contact Corporate & Foundation Relations in the Office of Development at [devcfr@mgh.harvard.edu](mailto:devcfr@mgh.harvard.edu) if you wish to submit a proposal in response to any of these opportunities. Note that proposals are still routed through the standard InfoEd/Research Management process.

Please be aware that any grant that brings in less than **15% in indirect costs (IDC)** will need to be supplemented up to the 15% equivalent by existing investigator or departmental sundry funds. Resolution of this issue must occur prior to submitting a proposal. Training fellowships from foundations, public charity, and non-profit organizations are excluded from this minimum IDC requirement.

**Have you updated your MGH Researcher profile?  
Go to <https://researchers.mgh.harvard.edu/> today!**

**1. Lawrence and Isabel Barnett Drug Development Program, ALS Association **NEW!****

The ALS Association's Barnett Drug Development grant program supports preclinical drug discovery and development of new or repurposed treatments for amyotrophic lateral sclerosis (ALS).

We are especially interested in drug discovery projects supporting the following:

- In vivo efficacy testing of lead molecules from pharmacological treatments, biological therapies, or gene therapy in animal models of ALS. Both novel programs and repurposing of approved or clinically safe therapies from other disease indications are appropriate for this RFA.
- Determination of dose-range finding, target engagement, pharmacokinetics, pharmacodynamics, and preclinical toxicology/safety.
- Development of pharmacologic agents through Adsorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) phase; This can be performed by a contract research organization in collaboration with the PI.

Please Note: Clinical trials will not be supported with this funding opportunity. Early drug discovery studies proposing high-throughput screening, hit-to-lead, and lead optimization will also not be supported through this funding opportunity.

Citizenship: Unspecified



Do you want to learn more about identifying external funding opportunities? Please [click here](#) to request a research consultation with **Amy Robb** or see ECOR's website for information on the [Pivot database](#).

Award Amount: \$500,000 paid over 2 years

Indirect Costs: 10%

LOI Deadline: April 23, 2021

(Invited) Application Deadline: June 25, 2021

Website: <https://www.als.org/research/funding-opportunities>

## **2. Milton Safenowitz Postdoctoral Fellowship, ALS Association **NEW!****

The ALS Association's Milton Safenowitz Postdoctoral fellowship grant program supports the development of new scientists in the field of ALS by funding junior postdoctoral fellows doing research of high scientific merit and relevance to amyotrophic lateral sclerosis (ALS).

We are especially interested in Fellowships supporting the following:

- Studies for new target validation including in animal models, and human cell models.
- Studies that would elucidate target or pathway biology in disease-relevant models, including defining upstream/downstream modifiers and convergence of promising target pathways.
- Studies of risk factors that could ultimately reduce the risk of developing ALS including studies of genetic risk factors, epigenetics, gene-environment interactions, lifestyle, occupational or dietary factors and epidemiology.
- Studies of new biomarker identification, and development and/or validation of biomarker assays.
- Studies to help people living with ALS, including development and/or validation of novel assistive technology and measurement of patient/caregiver/family burden.

PLEASE NOTE: Priority will be given to specific biological targets and areas of research not previously funded through this program in the last three years.

Citizenship: Unspecified

Award Amount: \$150,000 paid over 2 years

Indirect Costs: None

LOI Deadline: April 23, 2021

(Invited) Application Deadline: June 25, 2021

Website: <https://www.als.org/research/funding-opportunities>

## **3. LCRF-AstraZeneca Grant Program, Lung Cancer Research Foundation (LCRF) **NEW!****

Lung cancer continues to be the number one cause of cancer deaths worldwide, accounting for an estimated 136,000 deaths annually in the United States alone. Despite significant advances in lung cancer treatment, the disease remains the most common cancer killer of both men and women. New treatment modalities such as targeted therapies and immune therapies also pose new and unique challenges. To help address the most profound of these challenges, the 2021 LCRF-AstraZeneca grant program aims to fund innovative projects to:

- Understand primary and acquired resistance to osimertinib and novel combinations targeting concurrent driver mutations
- Develop more effective approaches to address disease progression in patients treated with durvalumab
- Discover novel biomarkers for predicting response to osimertinib or durvalumab and to identify patients who are at higher risk of recurrence (translational research preferred)
- Identify predictive biomarkers, understand the underlying biology and develop novel interventions for immune mediated adverse events, such as pneumonitis, in patients receiving durvalumab

Citizenship: Unrestricted

Award Amount: \$150,000 paid over 2 years

Indirect Costs: None

LOI Deadline: April 30, 2021

(Invited) Proposal Deadline: August 27, 2021

Website: <https://www.lungcancerresearchfoundation.org/research/funding-opportunities/>

#### **4. LCRF Pilot Grant Program, Lung Cancer Research Foundation (LCRF)**

Lung cancer continues to be the number one cause of cancer deaths worldwide, accounting for an estimated 136,000 deaths annually in the United States alone. Despite being the most common cancer killer of both men and women, lung cancer research remains critically underfunded. To help close this gap and improve outcomes, the goal of the LCRF pilot grant program is to fund innovative projects across the full spectrum of basic, translational, clinical, epidemiological, health services, and other research. 2021 LCRF pilot grants will provide funding over a period of two years for projects focused on one or more of the following topics:

- Lung cancer biology
- Prevention and screening for early detection
- Identification of new biomarkers
- Development of more effective and less toxic therapies including but not limited to targeted and immune-therapies
- Mechanisms of sensitivity and resistance to lung cancer therapies
- Supportive measures for people with lung cancer and their families
- Quality of care and outcomes research

Citizenship: Unrestricted

Award Amount: \$150,000 paid over 2 years

Indirect Costs: None

LOI Deadline: April 30, 2021

(Invited) Proposal Deadline: August 27, 2021

Website: <https://www.lungcancerresearchfoundation.org/research/funding-opportunities/>

## 5. Research Grant on Disparities in Lung Cancer, Lung Cancer Research Foundation (LCRF)

While scientific advances steadily continue to reduce lung cancer incidence and deaths, the disease disproportionately affects various groups such as African Americans, Native Americans, low socioeconomic status populations and people from certain geographic locations. Despite progress to reduce the burden of tobacco, disparities in tobacco-related morbidity and mortality remain, and inequitable receipt of evidence-based lung cancer care continues to compound these disparities. We encourage applications on a wide variety of disparities-related topics including but not limited to the following:

- Gender disparities in lung cancer burden
- Causes and risk factors for lung cancer among never smokers
- Influence of social and biological risk factors on lung cancer outcomes, access to and use of care, and quality of care
- Genetic and gene-environment interactions
- Interactions and contributions of multiple factors (e.g. smoking, genetics, environment, societal factors) to disparities in lung cancer outcomes
- Contribution of healthcare access and quality to disparities in outcomes
- Disparities related to other factors such as geography, socioeconomic status, and age

Citizenship: Unrestricted

Award Amount: \$150,000 paid over 2 years

Indirect Costs: None

Application Deadline: May 7, 2021

Website: <https://www.lungcancerresearchfoundation.org/research/funding-opportunities/>

## 6. Emerging Leader Award, Mark Foundation for Cancer Research

The Mark Foundation Emerging Leader Awards support innovative cancer research from the next generation of leaders. These grants are awarded to outstanding early career investigators to support high-impact, high-risk projects that are distinct from their current research portfolio.

Eligibility requirements (partial list):

- Applicants must be three to nine years from the start of an independent faculty research appointment as of December 31, 2021 (i.e., the official start date of the appointment must fall within the calendar years 2012-2018). Exceptions due to prolonged medical or family leave will be considered on a case-by-case basis. *Note that we have extended eligibility to nine years from the start of an independent faculty research appointment from the usual eight years to allow for applicants who may have been in their final year of eligibility in 2020 and did not apply due to impacts from the COVID-19 pandemic.*
- This award is not intended to be the main source of funding for the applicant's laboratory. Applicants must demonstrate multi-year independent funding that sustains the central activities of the laboratory (e.g., at least one or two grants such as NIH/R01, NSF/CAREER, or equivalently substantial multi-year awards). Individual eligibility will be determined during the review process.

Citizenship: Unrestricted

Award Amount: \$750,000 paid over 3 years

Indirect Costs: 10% included

LOI Deadline: May 3, 2021

(Invited) Application Deadline: July 26, 2021

Website: <https://themarkfoundation.org/emerging-leader-award/>

### **7. Research Grants, PSC Partners Seeking a Cure**

These grants are award to conduct research that addresses an important and novel, basic or clinical research question related to PSC and closely associated diseases (such as inflammatory bowel diseases (IBD) and cholangiocarcinoma). Our Research Grants Program seeks to encourage investigators to conduct research in promising new areas, with the goal that data generated will lead to federal (NIH) or external international funding.

Citizenship: Unrestricted

Award Amount:

- Research Grant: \$60,000 paid over 2 years
- Young Investigator Award: \$80,000 paid over 2 years

Indirect Costs: None

LOI Deadline: May 15, 2021

Application Deadline: July 15, 2021

Website: <http://pscpartners.org/research-grants/grant-application/>

### **8. NCS Research Training Fellowship Grant, The Neurocritical Care Society**

The Neurocritical Care Society (NCS) is pleased to announce a training fellowship for physicians, advanced practitioners, nurses, pharmacists, scientists, and others involved with neurocritical care. This program addresses the increasing need for early research career support in neurocritical care. The direct goal of this program is to foster initial support to individuals with high potential to become independent researchers. Specific goals of this funding mechanism pertain the development of mentorship ties, protection of research time, the pursuit of research training, and generation of preliminary data necessary to apply for subsequent scientist development training grants. Projects with a clinical or translational research focus are welcomed. The present award supports research efforts throughout a 12-month period, which will allow effective competition for subsequent training opportunities. It is expected that at the end of the award, the trainee will be in the process of submitting applications for national, peer-reviewed funding mechanisms to continue the research and research training.

Eligibility requirements (partial list):

- The study PI must be an active NCS member in good standing.

- Members in their early career stages (within 10 years after their last degree) are eligible to apply and must be at the Instructor or Assistant Professor level at the time of the award.
- In-training applicants may apply during training, but at the time of award the applicant must be in the early post-training professional career (Instructor or Assistant Professor level).

Citizenship: Unrestricted

Award Amount: \$77,000

Indirect Costs: 10%

LOI Deadline: April 23, 2021

Application Deadline: June 14, 2021

Website: <https://www.neurocriticalcare.org/research/grants/research-training-fellowship-grant>